Last reviewed · How we verify
NCT07149064
A Randomized, Triple-blind, Placebo Controlled, Parallel Clinical Trial to Investigate the Efficacy and Safety of Chronic Exposure to Nextida GC-B on Glycemic Control in Adults With Normoglycemia or Prediabetes
NA trial testing Nextida GC-B in Normoglycemia in 60 participants. Currently enrolling.
1 August 2026
Quick facts
| Lead sponsor | Rousselot BVBA |
|---|---|
| Phase | NA |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | triple |
| Primary purpose | treatment |
| Enrollment | 60 |
| Start date | 18 February 2026 |
| Primary completion | 1 August 2026 |
| Estimated completion | 1 August 2026 |
| Sites | 1 location across Canada |
Drugs / interventions tested
- Nextida GC-B
- Placebo
Conditions studied
- Normoglycemia — all drugs for Normoglycemia →
- Prediabetes — all drugs for Prediabetes →
- Glycemic Control — all drugs for Glycemic Control →
Sponsor
Rousselot BVBA — full company profile →
Who can join
18 and older, any sex, with Normoglycemia or Prediabetes. Healthy volunteers can join.
What's being measured
Primary outcomes are the specific endpoints the trial is designed to prove or disprove.
-
The difference in change in postprandial glycemic control between Nextida GC-B and placebo
Time frame: Day 0 to 90
The difference in change in postprandial glycemic control from baseline at Day 90 between Nextida GC-B and placebo as assessed by glucose incremental area under the curve (AUC) (iAUC 0-180 min). -
The difference in change in glycated hemoglobin (HbA1c) and glucose variability from baseline at Day 90 between Nextida GC-B and placebo
Time frame: Day 0 to 90
The difference in change in glycated hemoglobin (HbA1c) and glucose variability between Nextida GC-B and placebo
Sponsor's own description
The goal of this clinical trial is to investigate the safety and efficacy of Nextida GC-B on glycemic control in adults with normoglycemia and prediabetes. The main question it aims to answer is: What is the difference in change in postprandial glycemic control from baseline at Day 90 between Nextida GC-B and placebo as assessed by glucose incremental AUC (iAUC 0-180 min).
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT07149064
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other Rousselot BVBA trials
Trials by the same sponsor.
- NCT07195396 — To Collect Enriched Human Serum Following Hydrolyzed Collagen Intake · NA · completed
- NCT06937801 — To Assess the Effect of Collagen on Gastrointestinal Discomfort in Healthy Adults With Gastrointestinal Symptoms. · NA · completed
- NCT06789263 — Effect of a Collagen Hydrolysate on Postprandial Blood Glucose Profile, Gastric Emptying and GLP-1 Release in Normoglyce · NA · completed
- NCT06232460 — An Open Label, Dose-escalation Study, Assessing the Safety and Tolerability of a Collagen Peptide · NA · completed
- NCT05887791 — Effect of a Collagen Hydrolysate on Postprandial Blood Glucose Profile in Prediabetic and Healthy Subjects · NA · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07149064 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Rousselot BVBA
- Last refreshed: 12 March 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07149064.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing